Sackler Family Net Worth 2026: Inside the $11B Fortune

The Sackler family‘s net worth is estimated at $11 billion (range: $10–13 billion) as of October 2026. The fortune reads like two centuries of American enterprise folded into one pill: OxyContin, the time-release oxycodone Purdue Pharma launched in 1996, generated more than $35 billion in lifetime sales and lifted the Sacklers to the 16th-richest family in America. Between 2008 and 2018, while lawsuits gathered on the horizon, family members pulled an estimated $10.7 billion out of the company. And on May 1, 2026, the rebuilt $7.4 billion bankruptcy settlement took effect — the family paid more than $1.5 billion that day, with up to $6.5 billion of their own fortune committed over the next 15 years.

Early Life and Background

The Sacklers began in Brooklyn, New York, as the sons of Jewish immigrants who ran a small grocery and a dry-goods store. Three brothers would set the family’s course: Arthur, born in 1913; Mortimer, born in 1916; and Raymond, born in 1920. They grew up in a household where education was the escape route, and all three went into medicine — psychiatry, specifically, a field that in the 1940s was just becoming a serious market for drug companies.

Arthur was the oldest, the loudest, and the one who figured out first that the real money in medicine wasn’t in treating patients but in telling doctors what to prescribe. While still in medical school and residency, he was already writing and selling advertising to pharmaceutical companies. By the time his younger brothers finished their training — Mortimer and Raymond took medical degrees in Scotland — Arthur had a plan that would bind the three of them together for life: buy a small drug company and run it as a family enterprise. The partnership was formal, documented, and unusually durable: the brothers would remain co-owners for decades, and the family branches they founded still define who owns what today.

What matters for the money story is that this was never a startup that “got lucky.” The Sacklers arrived in pharmaceuticals with a specific and already-proven skill: selling drugs to doctors. Arthur had spent the 1940s and 1950s perfecting pharmaceutical advertising at a time when almost nobody else was doing it well. When the brothers bought their company in 1952, they weren’t buying a business so much as buying a stage for a marketing machine they already knew how to operate.

Education

Arthur Sackler earned his medical degree from New York University and trained in psychiatry, but his education that actually mattered was commercial: he learned, while still a student, how medical journals made their money from drug advertising and how weakly regulated that advertising was. He founded a medical advertising agency in 1946, before he had even finished his residency — a detail that tells you exactly where his attention was.

Mortimer and Raymond Sackler earned medical degrees in Scotland and trained as psychiatrists. Both returned to the United States and joined the family enterprise. The education split is one of the family’s defining facts: Arthur was the marketing mind and the rainmaker; Mortimer and Raymond were the physicians who gave the company its medical credibility. After Arthur’s death in 1987, the company passed entirely to the Mortimer and Raymond branches — a division that still determines which Sacklers owed what in the settlement.

The next generation’s education tells its own story about the money. Richard Sackler, Raymond’s son and the family’s most public face, earned his M.D. and joined Purdue’s leadership, becoming president in 1999 and chairman of the board in 2003. He was the one who oversaw the OxyContin launch years from inside the company — and later, the one whose internal emails and memos, disclosed in court proceedings, became the public record of how deeply family leadership was involved in sales strategy.

Career Journey

In 1952, the three brothers bought Purdue-Frederick, a small New York drug company that made laxatives and earwax remover. The purchase price was modest; the ambition was not. Arthur’s advertising agency already represented major drug companies, and he used that position to make Purdue-Frederick a serious business. His most consequential early campaign was for a tranquilizer: his work helped make Valium the first hundred-million-dollar drug in pharmaceutical history — the proof of concept for everything the family would later do.

The brothers also bought into the medical publishing business, acquiring the Medical Tribune newspaper and building it into one of the most-read publications in American medicine. This is the detail competitors usually skip and shouldn’t: the Sacklers didn’t just advertise to doctors; for a time, they owned one of the channels doctors read. It was a vertically integrated persuasion machine — the advertising agency, the medical newspaper, and the drug company, all under the same family’s control.

Through the 1960s and 1970s, Purdue-Frederick was a respectable mid-sized pharmaceutical company, selling a range of products including the painkiller MS Contin, an early controlled-release morphine. MS Contin matters because it was the dry run: a time-release painkiller, marketed to doctors who were reluctant to prescribe opioids. The company learned, pill by pill, how to sell controlled substances to a medical establishment that was officially nervous about addiction. When Arthur died in 1987, Mortimer and Raymond bought out his share from his estate, consolidating the company under the two surviving brothers’ branches. Arthur’s widow, Jillian, and their daughter Elizabeth kept his art and antiquities fortune — and, crucially, no stake in what Purdue was about to become.

Rise to Fame

OxyContin launched in 1996, and it detonated. The pitch was the controlled-release mechanism: oxycodone metered out over twelve hours, which Purdue presented as less prone to abuse than instant-release opioids. The company’s sales force blanketed doctors’ offices — at its peak, hundreds of representatives making millions of detail visits — and prescriptions soared. By 2002, OxyContin sales had reached roughly $1.5 billion a year, per Forbes’s reporting at the time. In 2012, more than 50 million opioid prescriptions connected to the Purdue marketing machine were being written annually. Across its lifetime, OxyContin generated more than $35 billion in sales, according to Forbes — a figure that made the Sacklers one of the richest families in American history.

The marketing relied on a claim that would become infamous: that addiction to the drug was rare. Purdue’s representatives cited a brief 1980 letter to the New England Journal of Medicine — five sentences by Porter and Jick reporting low addiction rates among hospitalized patients — and presented it to doctors as proof that “less than one percent” of patients would become addicted. The letter’s authors later said it had been misused. Internally, meanwhile, the company knew the twelve-hour dosing often wore off early, and its own guidance told doctors to prescribe stronger doses rather than more frequent ones — a decision documented in the litigation record and reported by the Los Angeles Times.

The wealth arrived fast and visibly. Forbes put the Sacklers on its America’s Richest Families list in 2015 at an estimated $14 billion, ranking 16th — ahead of the Rockefellers. The family name went up on the Met’s Egyptian wing, the Louvre, the Guggenheim, the Tate, and university buildings at Oxford, Harvard, and Yale. Then the lawsuits started arriving, and the same name that had bought immortality in marble became the most toxic brand in American philanthropy.

Main Sources of Income

Practically all of the Sackler fortune traces to Purdue Pharma distributions — not salaries, not stock sales, but the steady siphoning of profits from a privately held company the family controlled outright. Because Purdue was private, there were no public earnings reports and no shareholder votes; the family simply decided how much cash to take out each year. And in the decade before the bankruptcy, they decided to take out a great deal: an estimated $10.7 billion between 2008 and 2018, a figure established in the bankruptcy proceedings and cited by state attorneys general. Bloomberg Law’s reporting on court documents added the nuance competitors miss — about $10.8 billion shifted out from 2008 to 2017, but close to half went to taxes, leaving the family with roughly half that in net transfers.

The second engine was the international business. The Sacklers built Mundipharma, a network of companies selling opioids and other drugs across Asia, Latin America, Canada, and Europe, which Forbes noted brought in revenue comparable to Purdue’s U.S. haul. As part of the 2026 settlement, the family agreed to sell its international pharmaceutical holdings within seven years — court asset statements suggested the sale could generate roughly $3 billion after taxes, with up to $500 million of the proceeds flowing into the settlement itself.

The third engine was everything the Purdue money bought: securities portfolios, private equity, real estate in New York, Connecticut, London, and Switzerland, plus art and jewelry. Court filings showed the family still controlled about $8.7 billion in assets outside the drug industry even as the bankruptcy ground on — the reason the 2026 settlement could demand $6.5 billion from them personally without wiping them out.

Salary and Earnings

This is not a family that got rich on salaries, and the public record contains almost no individual paycheck figures — a deliberate feature of how they operated. The money moved as owner distributions, not W-2 income. The one hard number in the file is the aggregate: roughly $10.7 billion withdrawn from Purdue between 2008 and 2018, with the pace accelerating as litigation risk rose. In 2007, the same year Purdue pleaded guilty to federal charges and paid more than $600 million in fines, the family was already moving money out at a rate that would total billions over the following decade.

The individual branch figures are harder to pin down and honestly reported as such. Richard Sackler, the most prominent family member, has been the subject of repeated “$1 billion personal net worth” claims in the tabloid press — but as the finance site NetWorthBase correctly noted, no public financial statement confirms a personal figure for him, and the frequently cited “$11 billion” number is the combined family wealth, not his alone. What is documented is that eight Sacklers sat on Purdue’s board as recently as 2017–2018, collecting board compensation while directing the company’s strategy — and that by 2019, when Purdue filed for bankruptcy, the number on the board was zero.

The honest earnings picture, then: no salary table exists because none was ever published. The family’s income was the company’s profit, and the company’s profit was OxyContin — at peak, roughly $3 billion a year in revenue, mostly from that single drug, per Forbes’s reporting when the family joined the rich list.

Businesses and Investments

Purdue Pharma. The core asset and the whole story. Founded as Purdue-Frederick in 1892, bought by the Sacklers in 1952, renamed and rebuilt around pain management. OxyContin (1996) made it one of the most profitable private companies in America; the bankruptcy (filed September 2019) ended it. Under the 2026 plan, Purdue’s operations continue as Knoa Pharma, owned for the benefit of creditors, with the Sacklers permanently out and barred from selling opioids in the United States.

Mundipharma and the international network. The Sacklers’ overseas arm, selling opioids and other pharmaceuticals in dozens of countries. Forbes reported its revenues roughly matched Purdue’s U.S. business — making it a multi-billion-dollar asset in its own right. The family must sell it within seven years under the settlement terms, with proceeds split between the settlement and the family.

The offshore structure. The family’s money sits in a web of trusts and entities across jurisdictions including Switzerland — a New York prosecutor alleged as much as $1 billion moved to Swiss accounts, which the family called “perfectly legal and appropriate in every respect.” Mortimer Sackler Sr. died in Gstaad in 2010, and the family’s Swiss ties run deep. The structure worked exactly as designed for years: it kept the fortune intact and out of reach while Purdue itself went bankrupt.

Real estate and art. The visible assets include a manor house near Newbury, England — Stargroves, bought in 2012 for more than its £15 million listing price, an estate previously owned at different times by Mick Jagger and Rod Stewart — plus properties in New York, Connecticut, London, and the Swiss Alps. Arthur Sackler’s branch, separate from Purdue, holds one of the great private collections of Asian art, much of it donated to museums before the opioid litigation began.

Brand Deals and Sponsorships

The Sacklers never did endorsements — they did something bigger. They bought naming rights on the cultural establishment itself: the Sackler Wing at the Metropolitan Museum of Art, the Sackler name at the Louvre, the Guggenheim, the National Gallery in London, the Tate, and endowed positions at Oxford, Harvard, and Yale. The donations totaled hundreds of millions of dollars over decades, and for most of that time they purchased exactly what the family wanted: respectability, access, and a name associated with civilization rather than with pills.

The unwinding was swift and public. Starting with the Louvre in 2019 — the first major museum to remove the name — institutions fell in sequence: the Met stripped the Sackler name from its Egyptian wing in 2021, the Guggenheim and London’s National Gallery followed, and the Tate had already announced in 2019 that it would take no further Sackler money. The campaign was driven by the artist Nan Goldin and her group P.A.I.N., whose protests inside the museums’ Sackler-named spaces made the association a liability no board could ignore. No family in modern history has had its philanthropic brand dismantled so completely, and the episode is now a case study in how fast reputational capital can reverse.

What remains of the giving is court-ordered rather than voluntary. The settlement requires the Sacklers to forfeit control of family foundations worth about $175 million and to make public more than 30 million documents related to the opioid business — a transparency provision that will keep researchers busy for years.

Houses, Cars and Other Assets

The family’s property portfolio is the visible tip of the $8.7 billion in non-pharmaceutical assets documented in court filings. The best-documented holding is Stargroves, the English manor near Newbury bought in 2012 for more than £15 million — a 184-acre estate with rock-star provenance, previously owned by Mick Jagger and Rod Stewart. The family also holds or has held residences in Manhattan, Greenwich (Connecticut), London, and the Swiss resort town of Gstaad, where Mortimer Sackler Sr. died in 2010.

Cars barely register in the record — this is not a family that performed wealth through vehicles — but art does. Arthur Sackler’s collection of Asian art, assembled over decades, was among the finest in private hands; his widow Jillian donated major portions to the Smithsonian and other institutions. The Mortimer and Raymond branches hold their own collections, though the family has kept inventories private, and the settlement’s document-release provisions may eventually itemize what the public currently can only estimate.

The most consequential “asset” was never a house or a painting: it was the trust structure itself. Offshore trusts in multiple jurisdictions held the bulk of the withdrawn Purdue cash, and that structure is precisely what made the fortune so hard for plaintiffs to reach — and the settlement negotiations so protracted.

Awards and Achievements

This section reads differently from any other family’s. The Sacklers’ honors were real and numerous — Arthur Sackler was a major figure in medical publishing and advertising; the family’s philanthropy earned them museum wings, university chairs, and society-page reverence for half a century. Then the honors started being revoked. The name-stripping at the Met, the Louvre, the Guggenheim, and the National Gallery between 2019 and 2022 erased the most visible achievements the money had bought.

What remains in the record is commercial, not ceremonial: building Purdue-Frederick from a laxative maker into a company that generated $35 billion from a single product; creating the Mundipharma international network; and — the achievement nobody celebrates — constructing one of the most effective pharmaceutical marketing machines ever assembled, then one of the most effective asset-protection structures. The family’s true legacy, as the bankruptcy court record now shows, is a $7.4 billion settlement: the largest opioid resolution in American history, and the price of unwinding the fortune.

Net Worth Growth Over the Years

The trajectory is a rise, a plateau, and a court-ordered descent — and the dates matter because most net-worth pages still quote the peak.

The key insight: the headline number has barely moved since 2020 because it was always an estimate of assets, not cash — and the settlement takes its $6.5 billion out slowly, over 15 years, while the remaining assets keep earning. An expert witness for the state of Washington estimated during the earlier proceedings that the fortune could actually grow to $14.6 billion by the time the final installment is paid, as Bloomberg Law reported — markets rise, and the payments are staggered. Whether that proves true depends on the Mundipharma sale and the performance of the family’s securities portfolio, neither of which is public.

Social Media Presence

The Sacklers have no social media presence to speak of — and that absence is the point. For decades, the family was among the most private ultra-wealthy dynasties in America: no interviews, no profiles, no public-facing members. The strategy worked until the litigation forced disclosure. Richard Sackler’s 2015 deposition, his 2020 testimony before the House Oversight Committee, and the family’s internal emails — released through court proceedings — became the public’s only real window into how the fortune was managed.

What fills the vacuum is other people’s content: the artist Nan Goldin’s P.A.I.N. protests, Patrick Radden Keefe’s Empire of Pain (2021), the Hulu series Dopesick, and a steady stream of documentaries. The family’s one consistent public statement, repeated through lawyers for years, is that its members acted lawfully and ethically — a position the 2026 settlement neither confirms nor refutes, since it carries no admission of liability.

Personal Life

The family divides into three branches, and the division determines everything about the money. Arthur’s branch — his widow Jillian and daughter Elizabeth, an art historian — holds no Purdue stake and took no part in OxyContin; their wealth is art and philanthropy, and they have publicly distanced themselves from the pharmaceutical side. Mortimer’s branch — including his sons Mortimer Jr. and others — and Raymond’s branch — including Richard, David, and Jonathan Sackler and Raymond’s widow Theresa — owned Purdue, sat on its board, and are the parties to the settlement.

Richard Sackler, Raymond’s son, is the family’s public face by default: president of Purdue from 1999 to 2003, board chairman afterward, and the author of the internal memos — including the notorious “blizzard of prescriptions” line from the OxyContin launch era, disclosed in court papers — that made him the symbol of the family’s involvement. David Sackler, another of Raymond’s sons, testified in the bankruptcy proceedings and pushed back on claims about the fortune’s future, telling the court that nobody could say with certainty whether the family would emerge richer. The family lives between the United States, England, and Switzerland; Mortimer Sackler Sr. died in Gstaad in 2010, and the Swiss connection — trusts, accounts, residences — remains the least transparent part of the fortune.

No Sackler family member has faced criminal charges related to the opioid crisis, and the 2026 settlement explicitly carries no admission of liability. Purdue Pharma itself pleaded guilty to federal criminal charges in 2020 and was sentenced in April 2026 — the company took the criminal hit; the family paid in cash.

Sources & Reporting

Frequently Asked Questions

Published on October 15, 2026. Last reviewed October 2026. Found an error? See our corrections policy.